This phase III trial compared the safety and efficacy of amrubicin versus topotecan as second–line treatment for SCLC. Amrubicin did not improve survival when compared with topotecan in the second–line treatment of patients with SCLC. 

READ FULL ARTICLE Curated publisher From Mdlinx